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7Private Practice, 8320000 Santiago, Chile
8Implantology Program, University of San Sebastian, 8320000 Santiago, Chile
9Department of Periodontics, School of Dentistry, University of Granada, 18009 Granada, Spain
Correspondence should be addressed to Pablo Galindo-Moreno; pgalindo@ugr.es
Received 16 January 2015; Revised 7 April 2015; Accepted 14 April 2015
Academic Editor: Giulio Gasparini
Copyright © 2015 Miguel Padial-Molina et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Bone regeneration is often needed prior to dental implant treatment due to the lack of adequate quantity and quality of the bone
after infectious diseases, trauma, tumor, or congenital conditions. In these situations, cell transplantation technologies may help to
overcome the limitations of autografts, xenografts, allografts, and alloplastic materials. A database search was conducted to include
human clinical trials (randomized or controlled) and case reports/series describing the clinical use of mesenchymal stem cells
(MSCs) in the oral cavity for bone regeneration only specifically excluding periodontal regeneration. Additionally, novel advances
in related technologies are also described. 190 records were identified. 51 articles were selected for full-text assessment, and only
28 met the inclusion criteria: 9 case series, 10 case reports, and 9 randomized controlled clinical trials. Collectively, they evaluate
the use of MSCs in a total of 290 patients in 342 interventions. The current published literature is very diverse in methodology and
measurement of outcomes. Moreover, the clinical significance is limited. Therefore, the use of these techniques should be further
studied in more challenging clinical scenarios with well-designed and standardized RCTs, potentially in combination with new
scaffolding techniques and bioactive molecules to improve the final outcomes.
1. Introduction
Hard and soft tissues in the oral cavity are constantly being
challenged. As a consequence of infectious oral diseases,
trauma, tumor or cyst resection, or congenital and develop-
mental conditions (i.e., cleft palate defects), tooth loss results
in the alteration of basic functional, aesthetical, and psycho-
logical needs. Mastication, speech, swallowing, and thermal
and physical protection of important anatomical structures
(i.e., brain, nerves, arteries, and veins) are diminished [1].
In these situations, tooth replacement by osseointegrated
implants is an essential tool to restore the normal stomatog-
nathic system. However, quantitative and qualitative proper
bone architecture to allow successful implant treatment is,
unfortunately, sometimes compromised. If the adequate bone
is not restored previously to the implant treatment, itmay lead
to further complications [2, 3].
Bone deficiencies in the oral cavity differ enormously in
extension and etiology, ranging from localized alveolar bone
loss due to periodontal disease to extensive bone atrophy as a
consequence of a variety of syndromes, including traumatic
injuries and bone resorption associated with a number of
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benign or malignant tumors. Extensive bone deficiencies, in
particular, are really challenging in the clinical setting [4].
Bone regeneration requires the migration of specific cells
to the healing area to proliferate and provide the biological
substrate for the new tissue to grow. Soluble factors, differ-
ent cell types, extracellular matrix (ECM), and matricellu-
lar proteins mediate and coordinate this process. Initially,
angiogenic signals and new vascular networks provide the
nutritional base for tissue growth and homeostasis. Simul-
taneously, a three-dimensional template structure based on
a proper extracellular matrix is synthesized and organized.
This template will, later, support and facilitate the process of
bone formation and maturation. Once those structures are
established, the regenerated bonewill go on under the normal
homeostatic and modeling-remodeling processes [5, 6].
Although the exact mechanisms that regulate the bone
regeneration process at the deepest biomolecular level are
yet to be understood, several methods for predictable bone
reconstruction have been proposed [7], ranging from auto-
grafts, to allografts, xenografts, and alloplasts. These tech-
niques present different drawbacks including the limited
availability of autografts and their associated morbidity
in addition to the absence of cell populations carried by
allografts, xenografts, and alloplasts, which determine poor
osteoinductive properties. To overcome these limitations, the
use of growth factors incorporated in carriers, the stimulation
of the selective production of growth factors using gene
therapy, and the delivery of expanded cellular constructs are
being used in different areas of maxillofacial reconstruction
[8] (Figure 1). Cell therapy approaches constitute one of the
most promising instruments to enhance reconstruction of
both hard and soft tissues.
Stem cells are unspecialized cells with the ability to pro-
liferate and differentiate to multiple cell types when stimu-
lated by both internal and external signals. Adult (somatic)
stem cells that exhibit this plasticity are called pluripotent
cells and can be found in bone marrow in the form of
hematopoietic, endothelial, andmesenchymal (stromal) stem
cells (MSCs). Other sources of MSCs in adult patients have
been also identified such as adipose tissues (ASCs), lung,
and teeth (perivascular niche of dental pulp and periodontal
ligament) [9, 10] (Table 1). Mesenchymal and Tissue Stem
Cell Committee of the International Society for Cellular
Therapy proposes minimal criteria to define human MSC.
Firstly, MSC must be plastic-adherent when maintained in
standard culture conditions. Secondly, MSC must express
CD105, CD73, and CD90 and lack expression of CD45,
CD34, CD14 or CD11b, CD79a, or CD19 andHLA-DR surface
molecules. Thirdly, MSC must differentiate to osteoblasts,
adipocytes, and chondroblasts in vitro [11]. In this way, MSCs
can produce bone, cartilage, fat, or fibrous connective tissue
depending on their differentiation process [10] and, therefore,
are of most interest in the area of dental implantology.
Different technologies and application protocols are being
studied in this area. However, it is still needed to identify
the appropriate cell types, origin, and processing protocols as
themost critical determinants to achieve successful outcomes
[12]. Due to the limited availability of MSCs from bone











Figure 1: Schematic requirements for bone regeneration from a
tissue engineering perspective.
Table 1: Principal types and uses of cells in oral tissue regeneration.
Cell type Origin
Bone marrow stromal cells Autograft
Adipose stromal cells Autograft
Periodontal ligament cells Autograft, allograft, xenograft
Periodontal ligament stem cells Allograft, autograft
source for multipotent stromal/stem cells (adipose-derived
mesenchymal stromal/stem cells or ASCs) and has several
advantages compared to other sources of mesenchymal stro-
mal/stem cells (ubiquitous available, easy accessible source by
liposuction, and more abundant 0.5–2 × 106 AScs/g adipose
tissue) [13, 14].
Therefore, the main purpose of this review is to identify
the existing literature on clinical studies utilizing MSCs or
ASCs to treat oral bone defects and to critically analyze their
validity, methodology, and outcomes. Additionally, emerging
strategies for the recruitment and transplantation of MSCs
into bone defects will also be discussed.
2. MSC-Based Bone Regeneration
2.1. Materials and Methods. A search of electronic databases
including Ovid (MEDLINE), PubMed, and Cochrane Cen-
tral for studies was performed in September 2014 by two
examiners limited to articles published in English during the
last 10 years performed on human subjects. The search build
used was as follows: (“Mesenchymal Stem Cell Transplanta-
tion” [Mesh] OR “Adult Stem Cells” [Mesh] OR “Stem Cells”
[Mesh] OR “Stem Cells Transplantation” [Mesh] OR “Tissue
Therapy” [Mesh]OR “BoneMarrowTransplantation” [Mesh]
OR “Bone Marrow” [All Fields] OR “stem cell therapy”
[All Fields] OR “stem cell” [All Fields]) AND (“Sinus Floor
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Augmentation” [Mesh] OR “Bone Regeneration” [Mesh]
OR “Alveolar Ridge Augmentation” [Mesh] OR “craniofa-
cial bone regeneration” [All Fields] OR “craniofacial” [All
Fields] OR “alveolar bone” [All Fields] OR “implant site
development” [All Fields]) AND ((Controlled Clinical Trial
[ptyp] OR Clinical Trial [ptyp] OR Randomized Controlled
Trial [ptyp] OR Case Reports [ptyp] OR Comparative Study
[ptyp] OR Validation Studies [ptyp] OR Evaluation Studies
[ptyp]) AND “2004/09/12” [PDat]: “2014/09/12” [PDat] AND
“humans” [MeSH Terms] AND English [lang]).
In addition, a manual search was conducted in related
scientific journals and relevant papers that could contribute
to the process of information collecting.
The following inclusion criteria to select the articles
obtained after the search were as follows: human clinical
trial (randomized or controlled) and case reports/series on
the clinical application of MSCs in oral bone regeneration.
On the other hand, articles were excluded if the technique
applied was related to periodontal regeneration or was not
associated with bone tissue reconstruction. Articles were first
screened by analyzing the abstract. From those which were
selected in this phase, full-text was obtained and analyzed
for a second screening. Potential articles were independently
reviewed in full-text by two examiners. The final decision on
the included articles was made with mutual agreement of the
two examiners.
Additionally, a critical review of relevant supportive tech-
nologies for bone regeneration in combination with MSCs
has been conducted.
2.2. Results. A total of 190 records were identified by the
database and hand search and were assessed for eligibility.
After reading the abstracts, 51 articles were selected for full-
text assessment. Of those, only 28 were included in this
review based on the inclusion criteria previously determined.
From the 28 articles selected (Figure 2), 9 corresponded to
randomized controlled clinical trials [15–23] (Table 2), 9 to
case series [24–26, 32, 36–40], and 10 to case reports [27–
31, 33–35, 41, 42] (Table 3). Collectively, they evaluate the use
ofMSCs in a total of 290 patients/342 interventions.However,
due to the high variability among different variables, a meta-
analysis was not considered appropriate.
Bone deficiencies in the oral cavity differ enormously
in extension and etiology, ranging from localized alveolar
bone loss due to periodontal disease to extensive bone
atrophy as a consequence of a variety of syndromes, including
traumatic injuries and bone resorption associated with a
number of benign or malignant tumors. In these clinical
scenarios, functional and esthetical rehabilitation by dental
implants is an essential tool. However, a proper quantity
and quality of bone is a prerequisite not always present
[1]. Therefore, different regenerative techniques have been
proposed in these scenarios aiming at achieving predictable
outcomes. Extensive bone deficiencies, in particular, are
really challenging in the clinical setting. Fortunately, cell
transplantation strategies can provide a viable treatment
option to overcome the limitations of autograft harvesting






















database and hand search
(n = 190)
Assessed (n = 190)
Excluded not meeting the
inclusion criteria (n = 139)
Full-text assessment (n = 51)
Excluded not meeting the
inclusion criteria (n = 23)
Studies included (n = 28)
Figure 2: Flow chart of the paper selection process.
constitute one of the most promising instruments to enhance
reconstruction of both hard and soft tissues [43, 44].
Bone regeneration requires not only osteolineage pop-
ulations to migrate, proliferate, and differentiate into the
treated area but also, of extreme importance, angiogenesis
to provide the adequate nutrients and environment in which
the bone tissue can grow and develop [12, 45]. Because
of this, stem cells have gained interest due to their capac-
ities to differentiate to a variety of cell lineages, includ-
ing hematopoietic, mesenchymal, and endothelial cells [10].
Stem cells can be found in different tissues, such as bone
marrow, adipose tissue, and, in the oral cavity, periodontal
tissue, dental pulp, and dental follicle [8] (Table 1). How-
ever, due to the limited autogenous availability in some
of those locations, only bone marrow and adipose-derived
mesenchymal stromal/stem cells have been clinically applied
to bone regeneration in the oral cavity. Although different
technologies and application protocols are being studied
in this area, the optimal cell type, origin, and processing
protocol are yet to be identified [12].
The analysis of the published literature on the clinical
use of MSCs for oral bone regeneration previous to dental
implant placement highlights the lack of proper RCTs with
comparable methodologies to extract proper overall conclu-
sions. However, out of the 28 identified clinical studies, 25
report the use of iliac bone marrow aspirates (BMA) which
reflects that this location is widely accepted as the current
standard for aspirate harvesting [16–30, 33–42]. In fact, BMA
from the iliac crest has been confirmed as the harvesting
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techniquewith lessmorbidity and better patient comfort than
the traditional bone harvesting from the same location [19].
However, there is no standardization in terms of the
processing and handling of such aspirates. While some
studies use an expansion and isolation protocol previous
to the surgical implantation (with a variety of subculture
times, culture supplementations, automated or manual pro-
cesses, cell population selection, etc.), others do the aspirate
intrasurgically (chairside) and use the whole aspirate or a
commercially available concentration kit (to select endothe-
lial progenitors, hematopoietic and mesenchymal stem cells,
platelets, lymphocytes, and granulocytes) (BMAC Harvest
Technologies Corporation, Plymouth, MA, USA). One RCT
compared the use of nonprocessed BMA versus PRP or
CD34+ cells (angiogenic cells isolated from a BMA). Radio-
graphic results from this study confirmed the utility of BMA
and CD34+ over PRP alone [23]. However, to our knowledge,
no clinical comparison has been done between processed
BMA and nonprocessed BMA, which will be of high interest.
In this sense, results from 2 RCTs [20, 21] show a similar
achievement in postextraction socket reconstruction in terms
of horizontal and vertical augmentation, even though the cell
concentration procedure was performed by an automatic cell
culture system (that specifically increases the proportion of
bone repair cells, that is, hematopoietic and mesenchymal
stem cells) (Ixmyelocel-T, Aastrom Biosciences Ann Arbor,
MI, USA) [20] or a chairside technique including the whole
aspirate with no concentration step [21].
Another important difference amongst studies is the
carrier used to deliver the cells. It ranges from alloplastic graft
(𝛽-TCP or HA) to xenograft (mainly bovine bone), allograft
or autograft (either PRP concentrate or autogenous bone).
Other studies use a combination of those materials, with or
without the addition of additional factors such as PDGF or
BMP-2. No standardization is found on the use of a covered
membrane over the grafted area either.
Additionally, different defects are being treated in
these studies. Those defects range from extensive non-self-
contained (cleft palate and tumoral postresection defects)
to extensive self-contained (sinus lift), nonextensive self-
contained (postextraction sockets), and nonextensive non-
self-contained defects (vertical and horizontal alveolar ridge
augmentation). Bone regeneration in these situations differs
enormously from one to another.
Globally, the results in most of the available literature
show the goodness of the technique by vague subjective
indications of qualitative appreciations and some studies fail
to report specific objective quantitative data. When they do,
the reported data is not comparable either as it ranges from
vertical, to horizontal, or volumetric measures. Additionally,
these measures are presented in absolute magnitudes or % of
gain or reduction depending on the study. On the other hand,
the number of differences among the identified RCTs makes
it difficult to make a fair global comparison. Only 2 of those
RCTs are fairly comparable as they use similarmethodologies
for concentration process (chairside), cell origin (iliac crest),
defect type (sinus lift), and control group (bovine bone +
autogenous graft) [16, 17]. From both studies that globally


















Figure 3: Weighted mean percentage of vital bone from RCTs on
sinus lift [15–17]. No overall statistical significance difference was
found (𝑝 = 0.085, Student’s 𝑡-test).
it can be concluded that the combination of bovine bone plus
BMA concentrated chairside provides a higher radiographic
volume gain of 1.74 ± 0.69 versus 1.33 ± 0.62mL (test versus
control, 𝑝 < 0.02) [17] and better histological outcomes in
terms of new bone formation 17.7± 7.3 versus 12.0± 6.6% (test
versus control, 𝑝 < 0.026) [16]. Sauerbier et al. [17] reported
no histological differences (12.6 ± 1.7 versus 14.3 ± 1.8%; test
versus control, 𝑝 = 0.333). Other studies on sinus lift also
show histological advantage of using stem cells carried in an
allograft cellular bonematrix in this location (new vital bone:
32.5 ± 6.8% versus 18.3 ± 10.6%, test versus control) [15]. The
weighted mean percentage of vital bone obtained by these
studies is not statically different from control (9.14 ± 7.02) to
test group (18.02±9.1) (𝑝 = 0.085, Student’s 𝑡-test) (Figure 3).
The differences are even more diffuse if other studies treating
other defect locations are included in this comparison. This
highlights the necessity for better-designed studies to reduce
bias and variety of data and ultimately enables consensus in
this field.
In summary, the main overall report findings were that
the clinical application of stem cells for oral bone regener-
ation promotes better outcomes in terms of clinical, radio-
graphic, and histological parameters. However, the clinical
significance in the applications analyzed in those RCTs
(mainly self-contained defects, that is, postextraction sockets
and sinus floor elevation) is very limited. Therefore, it could
be argued that (1) the use of stem cells is not necessary in small
defects that can be successfully treated by othermeans and (2)
the lack of conclusive advantages does not surpass the scien-
tific doubts, morbidity, and potential complications that stem
cell therapy may possess. Therefore, the generalizability for
the use of stem cell therapy in the daily clinical setting is still
to be confirmed and probably not recommended for many
clinical cases. Its advantages are yet to be studied in more
challenging scenarios, such as extensive non-self-contained
10 BioMed Research International
defects (vertical alveolar bone augmentation, extensive bone
deficiencies in postresection tumor defects, and cleft palate
conditions) where theymay show their greatest potential over
current treatment options.
3. Novel Supportive Strategies for the Use of
MSCs in Bone Regeneration
The clinical use of MSCs for oral bone regeneration is
usually accompanied by supporting scaffolds and bioactive
molecules to further increase the capabilities of cell-based
therapies.
3.1. Scaffolds for Bone Regeneration. The main purpose of a
scaffold is to provide a mechanical support for cell migration,
proliferation, and activity by mimicking the ECM. They will
stimulate the production and maturation of a new ECM that
will eventually mineralize. A scaffold will ideally provide a
template for the subsequent bone formation, which starts
in the periphery and continues towards the inner part.
In this process, porosity is of extreme importance since
it will facilitate cell ingrowth and vascularization and the
biodegradation process [46]. Additionally, surface chemistry,
surface charge, and topography are also important in the
interactions between cells andmaterial for bone tissue growth
[5, 47].
Conventional scaffolds naturally derived (autografts, allo-
grafts, and xenografts) or synthetic materials (alloplasts)
are commonly used in bone regeneration and implant
therapy [5]. However, clinical needs of full control of the
regeneration process, focus, and orientation and in large
defects cannot be successfully achieved by this classic or
conventional approach. Fortunately, additive manufacturing
processes allow full control of porosity features, 3D structure,
and surface properties of the synthesized material and it
is, therefore, being the focus of extensive research [48].
They can be combined with cell-, growth factor- or gene-
based approaches to serve as supportive carriers and induce
stimuli for tissue formation [49]. 3Dprinted scaffolds can also
mimic stem cell niches to regulate daughter cell proliferation,
differentiation, and dispersion into the surrounding tissue
or by attracting useful cells to a desired anatomic site [49,
50].
Additive manufacturing is defined as the process of
joining materials to make objects from 3D model data,
usually layer upon layer, as opposed to subtractive manufac-
turing methodologies [51]. Usually, 3D printing is used as a
synonym since it is the most widely used. However, addi-
tive manufacturing also includes other scaffold fabrication
techniques such as solid freeform fabrication (SFF) and rapid
prototyping (RP) that use deformation and solidification,
polymerization, laser-assisted sintering, or direct writing-
based processes to create the final scaffold [52]. Additive
manufacturing relies upon computer-based scaffold design
and fabrication [53]. This image-based design technology
can be used to define virtual three-dimensional models of
anatomic geometry of the defect and to create a template
for the scaffold on a global anatomic level [54]. By additive
manufacturing, the heterogeneous structures to be regener-
ated can be mimicked by variations in macro-, micro-, and
nanostructures and scaffold surface topography, which will
influence the modulus of elasticity, permeability, and cell
orientation [55–57].
For bone regeneration, a large variety of ceramic, poly-
meric, and composite materials can be processed using 3D
printing to control interconnected porosity [52]. Among
these, calcium phosphates are the main materials used in
bone engineering. Of them, hydroxyapatite (HA) is the most
used and studied ceramic material in the dental field [8].
HA possesses an excellent bioactivity, osteoconductivity and
is similar to bone in composition. It can stimulate BMP-
2 expression in a pathway dependent on the p38 MAP
kinase [58], increase of capillaries and vessel formation, and
homogeneous osteoconduction from central channels with
no cytotoxicity and adequate cell adhesion [59]. Hydrox-
yapatite customized scaffolds can be combined with MSCs
to achieve better results than those obtained with controls
[60]. Similarly, 𝛽-tricalcium phosphate, a synthetic inor-
ganic calcium-phosphate-based material, has demonstrated
an increase of human osteoblasts ingrowth, proliferation,
and new bone formation [61] with adequate biocompatibility
also confirmed by tartrate resistant acid phosphatase (TRAP)
staining and lacunae formation [62].
Synthetic polymers in bone tissue engineering are very
flexible [63]. Property modification, control of macrostruc-
ture, degradation time and release mechanism, and exposure
duration of bioactive molecules can be better controlled
with these materials [64–66]. It is possible to maintain the
therapeutic levels of encoded proteins and to limit unwanted
immune response and potential side effects.Themost studied
synthetic materials for additive manufacturing are the group
of poly(lactic-co-glycolic acid)based (PLGA) biomaterials.
This material has been successfully used for the regeneration
of complex bone-ligament interfaces with rapid prototyping
techniques [54, 55, 67]. Other polymers under study are
the group of poly(ethylene glycols) and poly(𝜀−caprolactone)
methyl ethers. They can be combined with cell transplanta-
tion and hydroxyapatite to increase the mimetic properties
and, therefore, improve bone regeneration results, specifically
in terms of mechanical strength [68].
Based on these properties, the use of 3D printing in
fabricating scaffolds with live osteoprogenitor cells [69] and
the controlled delivery of specific growth factors such as
BMP-2 [59, 70], collagen, and chondroitin sulfate [71] or other
drugs like tetracycline [72] are being explored. The potential
application is to reduce the dose of those molecules, control
the release pattern, and reduce side effects. Bioprinting,
however, is still at a very early stage and much research is yet
to be done.
3.2. Bioactive Molecules and Gene-Therapy Techniques. The
delivery of growth factors and other bioactive molecules
was the first approach into using a biological agent modifier
for regeneration purposes [73]. A number of factors, such
as platelet derived growth factor (PDGF), fibroblast growth
factor (FGF), insulin growth factor (IGF), bonemorphogenic
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Figure 4: Osteopontin immunohistochemical detection on anor-
ganic bovine bone particle (Bio-Oss). Note bone formation where
intense interstitial expression of OPN is observed in a case of
maxillary sinus floor elevation (micropolymer peroxidase-based
method, original magnification ×20).
proteins (BMPs, specially BMP-2 and BMP-7), periostin,
vascular endothelial growth factor (VEGF), and transforming
growth factor beta (TGF-𝛽), are present in the healthy
bone matrix and are expressed during bone healing [74].
They regulate vascularization and induce proliferation and
differentiation of osteoprogenitors cells [52, 61, 70] and sur-
rounding tissues in the periodontal and gingival structures
[75–78]. Therefore, they can be useful for improving the
healing processes and to stimulate bone regeneration and
have extensively studied and reviewed elsewhere [8, 49].
In addition to thementioned growth and/or transcription
factors and regulators of osteogenesis, our group has recently
initiated efforts in investigating the potential of twomolecules
that can be of interest in this topic aswell. Osteopontin (OPN)
is a highly phosphorylated sialoprotein abundant in the
mineralized extracellular matrices of bones and teeth [79].
OPN, mainly through its RGD region, stimulates cell activity
to influence, amongst others, bone formation, remodeling,
and maintenance as well as angiogenesis [80]. In bone, it
is primarily synthesized by cells of osteoblastic lineage and
in wound healing sites [81] where it interacts with the cell-
surface receptor CD44 [82]. This interaction has been shown
to increase MSCs recruitment to the bone healing area [83].
Previous findings related OPN expression to the presence
of CD44-positive cells in anorganic bovine bone (ABB)
particles in samples from sinus floor augmentation. OPNwas
found on the interstitial boundary of new bone with ABB,
inside lacunae spaces, bone canaliculi and in osteocytes in
trabecular bone without expression in the trabecular bone
or the interstitium [84, 85]. Therefore, combining scaffold
modificationwith the delivery of bioactivemolecules, it could
be possible to include OPN in ABB particles to increase bone
regeneration in vivo (Figure 4).
Another important attractor of MSCs to the bone heal-
ing area is Musashi-1. Musashi-1 is an osteogenic marker
expressed in osteoblasts (cytoplasm and nuclei) and osteo-
cytes (nuclei) (Figure 5). It binds to RNA as a translational
regulator in MSCs with osteogenic capacities. It could there-
fore be delivered to increase recruitment and differentiation
Figure 5: Immunohistochemical expression of Musashi-1 in
fusocellular cells, osteoblasts, and osteocytes in a case of maxillary
sinus floor elevation with anorganic bovine bone (micropolymer
peroxidase-based method, original magnification ×20).
of osteogenicMSCs [86].These activities are still at their very
infancy and more research is needed.
However, an important drawback of these described
methods is the difficulty in activating the right process at the
right location in the right cells at the right time for a sufficient
amount of time, while minimizing adverse reactions [87].
Important advances have been made to overcome these
limitations. Some of the most promising strategies are those
designed to activate the protein release from the scaffold [88]
or the activation of the bioactive molecule [89] “on demand”
by an external source or trigger. Different methodologies
are under study, including the activation by changes in
pH, proteases activity, and energy-based stimuli such as
magnetism, electricity, light, and temperature [88]. Focused
ultrasound is an emerging clinical technology primarily used
for the thermal and/or mechanical ablation of cancerous
or precancerous tissues deep within the body that can be
focused on small volumes and generate spatially restricted
regions of hyperthermia by coupling a magnetic resonance
imaging (MRI) instrument to an integrated high intensity
focused ultrasound (HIFU) transducer. HIFU has also been
successfully used to achieve spatial and temporal control of
the production of VEGF and BMP-2 in vitro and in vivo
[89, 90]. With such technology, scaffolds, cells, bioactive
molecules, and gene therapies could be suitable for a 4D
control. The implications of this approach range from the
identification of spatiotemporal patterns of gene expression
during development to, more importantly within the aim
of this review, the application of those patterns for bone
regeneration in vivo as a future clinical tool.
3.3. Perspectives on Platelets and Fibrin Gels for Combined
Therapies. In last decades, many different approaches have
been attempted for the use of autologous platelet concentrates
that serve as both carrier and metabolic stimulators through
their high concentration of growth factors [91]. Despite the
specific differences between them in terms of concentration
procedure, coagulant treatment, separation of blood phases,
and so forth [92], they have been tested in many different
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clinical fields, such as oral and maxillofacial surgery, ear-
nose-throat surgery, plastic surgery, orthopaedic surgery,
sportsmedicine, gynecologic and cardiovascular surgery, and
ophthalmology [91, 93]. In the literature, their clinical and
experimental results are often controversial and difficult to
sort and interpret [94, 95], mostly because of the lack of
proper terminology betweenmany different families of prod-
ucts, often wrongly regrouped under the inaccurate generic
term PRP (platelet-rich plasma) [92]. Recent terminology
and classification regrouped these techniques into 4 families
depending on their fibrin architecture and cell content [92,
96, 97]: pure platelet-rich plasma (P-PRP), leukocyte- and
platelet-rich plasma (L-PRP), pure platelet-rich fibrin (P-
PRF), and leukocyte- and platelet-rich fibrin (L-PRF).
The 2 families of PRPs are first of all platelet suspensions,
which can jellify after activation like a fibrin glue [96, 98]; as
it was discussed previously, the PRP fibrin gels were tested as
scaffolds for MSCs, as fibrin gels are quite common scaffolds
in tissue engineering [91]. On the other hand, the 2 families of
PRF only exist in a strongly polymerized fibrin gel form [99].
P-PRP and P-PRF do not contain leukocytes or any other cell
bodies outside of platelets, while L-PRP and L-PRF contain
leukocytes and various populations of circulating cells [99].
This classification is interesting to correlate with Figure 1,
as it highlights the fact that the products from the L-
PRF family present all the schematic requirements for bone
regeneration from a tissue engineering perspective: cells
(leukocytes and many other cell populations) [99], scaffold
(fibrin blood clot, often used in bone tissue engineering
experiments) [100], and bioactive molecules (growth factors
and all the molecules available in platelets, plasma, and
leukocytes for starting) [101]. L-PRF has also this particularity
to integrate very naturally all these elements, leading to the
slow release of growth factors from the L-PRF fibrin matrix
and the production of growth factors from the cells living
in the gel [98, 101, 102]. For these reasons, L-PRF was often
described as an optimized natural blood clot [99], and, as it
is often said in orthopedics, there is no good bone healing
without adequate bleeding.
Specifically, within the context of this review, it is impor-
tant to highlight the fact that L-PRF was tested with oral
bone mesenchymal stem cells in vitro [103] and revealed
itself as a dose-dependent stimulator of proliferation and
differentiation of these cells. This result was described also
in other studies with osteoblasts [100]. It was considered
as the consequence of the coculture between the bone cells
and the leukocytes of the L-PRF [100, 103], in the presence
of the fibrin matrix and growth factors of the L-PRF clots
[98], resulting in complex but natural interactions promoting
bone regeneration. L-PRF is therefore in itself an interesting
model fulfilling the requirements for bone regeneration
presented in Figure 1, and it probably explains that it has
been demonstrated to be successful in the treatment of
bone defects [94, 95, 104–106], for example, as sole grating
material in maxillary sinus floor elevation [107–109]. As an
interesting perspective of combined therapy, it seems that one
promising novel supportive strategy for the use of MSCs in
bone regeneration may be as simple as an optimized L-PRF
natural blood clot.
4. Conclusion
Bone regeneration based on tissue engineering approaches
has a solid background for clinical application in human bone
defects. The cell-based, scaffold, bioactive molecule delivery
and gene-therapy methods interface and complement each
other. However, some of these therapies are still at the pre-
clinical level.
As presented in this paper, many different approaches
and biologic agents are being studied. The major challenge
for all of them is the timely and sequential organization of
events that need to occur in the healing area. The aim is
to promote the adequate processes at the precise moment
without compromising the normal cell function and overall
process. External “on demand” activation technologies are
being developed. Additionally, the need for custom medical
devices that can be adapted for the patient and the bone defect
specific clinical needs will increase the use of 3D printing in
the coming years. The association of these techniques with
cell-based, bioactive molecules and gene-therapy approaches
is a promising and exciting area of research.
However, the current published literature on the clinical
application of stem cells for craniofacial bone regeneration
is abundant but highly diverse, which reflects (1) the fact
that these technologies are relatively new and, therefore, it
is difficult to standardize findings and clinical applications;
and (2) the number of different potential applications to
successfully use cell therapy in the clinical practice is high but
still needs to be scientifically proven.
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